Guardant Health Expands Tissue-Free Reveal Test to Monitor Late-Stage Therapy Response in Cancer Patients

Guardant Health expands its Guardant Reveal blood test to include late-stage therapy response monitoring for patients with solid tumors. The test uses circulating tumor DNA levels to predict treatment outcomes and can be initiated at any time during treatment, offering clinicians actionable insights in just seven days. The expanded offering is clinically validated in confirming effective therapies and optimizing treatment faster in patients with advanced cancer.